FLT3 and acute myeloid leukemia: FLT3-TKD point mutations in the FLT3 drug binding site have been previously associated with resistance to FLT3 inhibitors [11]; however, we failed to detect such mutations in the FLT3 gene in EC-70124-resistant AML cells.